Few aspects of health have been translated into numbers as thoroughly as the cardiovascular system. Blood pressure comes back as two numbers, cholesterol as a panel of values, and physiological tracking has increasingly moved onto the wrist. In 2026, 37% of U.S. adults reported owning a smartwatch. Those measurements have made cardiovascular risk more visible, but the blood vessels producing and responding to many of those signals remain largely out of sight.
What eventually becomes visible is already remarkably common. Between August 2021 and August 2023, 47.7% of U.S. adults had hypertension, including 23.4% of adults aged 18–39 years, 52.5% of those aged 40–59 years, and 71.6% of those aged 60 years or older. Among adults with hypertension, only 20.7% had blood pressure controlled below 130/80 mm Hg. The presence of hypertension in nearly one in four adults younger than 40 makes vascular dysfunction difficult to dismiss as something that begins only in old age.
Blood vessels, however, are not inert conduits waiting to become narrowed or stiff. Their inner surface is lined with a continuous layer of endothelial cells that regulates vascular tone, hemostasis, permeability, inflammatory activity, angiogenesis, and interactions between circulating cells and the vessel wall. These cells continually respond to mechanical and chemical information from the blood, releasing relaxing and contracting factors that help adjust vessel diameter and blood flow as physiological conditions change.
That ability to respond is one of the first things that can begin to deteriorate. When blood flow increases, mechanical forces on the endothelial surface stimulate pathways that include endothelial nitric oxide synthase (eNOS) and the production of nitric oxide (NO), which relaxes vascular smooth muscle and helps the vessel dilate to accommodate changing demand. NO also helps regulate platelet activity and inflammatory interactions within the vessel wall. Endothelial dysfunction can therefore appear as more than impaired dilation: it can include reduced NO availability, inflammatory activation, leukocyte adhesion, increased permeability, thrombogenic activity, and other changes that precede the obstructive arterial disease that becomes clinically obvious later.
Redox regulation is one reason that loss of responsiveness can become self-reinforcing. Superoxide can react with NO, reducing the amount available for vascular signaling while generating peroxynitrite; peroxynitrite can in turn oxidize tetrahydrobiopterin (BH₄), a cofactor required for normal eNOS activity. When BH₄ becomes insufficient, eNOS can become “uncoupled” and produce superoxide rather than NO, further shifting the vessel away from normal vasodilator signaling. This is not simply a matter of eliminating reactive oxygen species, which also participate in normal vascular signaling. The problem is the loss of redox control that allows physiological signaling to become progressively disruptive.
Over time, the problem can move from how a vessel responds to what the vessel itself becomes. Persistent endothelial dysfunction and inflammation can alter communication with vascular smooth-muscle cells, which can change their contractile behavior, growth, morphology, and interactions with the extracellular matrix. Remodeling can narrow the internal diameter of resistance arteries, while changes in smooth muscle, collagen, elastin, and extracellular matrix contribute to increasing stiffness in larger vessels. Blood pressure then becomes both consequence and contributor: impaired relaxation, increased peripheral resistance, vascular remodeling, inflammation, and oxidative stress can promote hypertension, while sustained pressure places additional mechanical stress on the vessel wall and drives further remodeling. A blood-pressure reading can therefore reflect the accumulated behavior of a vascular system that has been changing long before the cuff identifies the result.
Human molecular-hydrogen (H₂) studies have begun to test vascular function at this earlier level. One of the earliest human studies tested vascular function directly. Thirty-four participants were randomized to hydrogen-rich water or placebo water, and brachial-artery flow-mediated dilation increased from 6.80% to 7.64% after consuming water containing 3.5 mg of dissolved H₂, while it decreased from 8.07% to 6.87% in the placebo group. Flow-mediated dilation measures how strongly an artery widens in response to the increase in blood flow that follows temporary occlusion and release, so the finding captured a change in vascular behavior rather than simply a change in a circulating biomarker. A later randomized trial extended that observation into the smaller vessels of the peripheral circulation. Sixty-eight healthy volunteers received either placebo water or 500 mL of water containing 3.5 mg of H₂, with reactive hyperemia measured in the fingers before treatment, one hour and 24 hours after the first dose, and after two weeks of daily consumption. The logarithmic reactive hyperemia index increased by 22.2% from baseline after 24 hours and by 25.4% after two weeks in the H₂ group. The two trials used different methods and examined different parts of the peripheral circulation but they converged on the same functional feature: how strongly vessels responded when blood-flow conditions changed.
The vascular findings become more clinically relevant in people with established hypertension. In a randomized placebo-controlled trial, 60 adults aged 50–70 years with hypertension were assigned to inhale air or a hydrogen–oxygen mixture for four hours per day over two weeks. In the H₂–O₂ group, right-arm systolic pressure declined from 151.9 to 147.1 mm Hg and left-arm systolic pressure from 150.7 to 145.7 mm Hg, while nighttime ambulatory diastolic pressure fell by an average of 2.7 mm Hg. Significant corresponding changes were not observed in the air group. Angiotensin II, aldosterone, cortisol, and the aldosterone-to-renin ratio also declined from baseline after H₂–O₂ inhalation, suggesting that the response was not confined to local vessel dilation but occurred alongside changes in hormonal systems involved in blood-pressure regulation.
A much larger 2024 study examined hydrogen inhalation alongside routine antihypertensive treatment in real-world clinical practice. After propensity-score matching, 2,364 Chinese adults with hypertension were followed for 24 weeks, and those receiving hydrogen inhalation had progressively greater reductions in blood pressure than matched patients receiving routine treatment without H₂. By week 24, the between-group difference was 7.81 mm Hg for systolic pressure and 2.89 mm Hg for diastolic pressure, and the H₂ group was more likely to have controlled blood pressure at each follow-up point.
Experimental work suggests that blood pressure may not capture the full vascular response. In spontaneously hypertensive rats, three months of hydrogen-rich saline improved endothelial function and reduced aortic hypertrophy without significantly lowering blood pressure. The same animals showed reduced oxidative and inflammatory signaling, improved mitochondrial function and baroreflex regulation, and changes associated with greater NO bioavailability. The vessel could therefore function differently even when the pressure measured inside it did not.
Other experiments move beyond dilation into the different jobs performed by the endothelium. In cultured vascular endothelial cells exposed to an inflammatory stimulus, hydrogen-rich medium reduced monocyte and neutrophil adhesion, lowered expression of adhesion molecules, and preserved vascular endothelial cadherin and electrical resistance across the endothelial layer, indicating less disruption of the vascular barrier. In LDL-receptor-deficient mice fed a high-fat diet, hydrogen-rich water reduced endothelial expression of the senescence markers p16 and p21, together with macrophage infiltration and TNF-α expression in atherosclerotic lesions. These findings remain preclinical, but they extend the H₂ response from vascular tone into inflammatory activation, barrier integrity, and the longer-term condition of the vessel wall.
There are also signs that these cellular effects can reach the level of tissue perfusion. In a mouse model of peripheral arterial disease produced by hindlimb ischemia, hydrogen-rich water accelerated recovery of blood flow, increased capillary and arterial density in ischemic muscle, and increased cyclic GMP, an important downstream component of NO-mediated vascular signaling. Separate experiments found that H₂ restored proliferation, migration, and tube formation in damaged endothelial progenitor cells through signaling involving PI3K, AKT, and eNOS, processes relevant to the formation and repair of vascular endothelium.
Taken together, the H₂ studies point toward vascular health as a dynamic capacity rather than a fixed measurement. In humans, H₂ has been associated with changes in flow-mediated dilation, peripheral reactive hyperemia, and blood-pressure regulation, while experimental studies extend those findings into NO signaling, endothelial inflammation, barrier integrity, vascular senescence, repair, and recovery of tissue perfusion. The studies differ substantially in population, route of administration, duration, and experimental setting, and the human evidence remains limited. Even so, the findings repeatedly converge on processes that determine whether a blood vessel can still sense a change, respond appropriately, and maintain its function under stress.
A blood-pressure reading captures a moment. The vessel wall is working every moment. It has to detect changing demand, release the signals that alter blood flow, keep circulating cells on the correct side of the endothelial barrier, withstand mechanical and inflammatory stress, and repair itself when that stress causes damage. Those abilities can begin to change long before vascular health is reduced to a single abnormal number. The emerging H₂ research is compelling because it reaches into that largely unseen period, not simply where vascular dysfunction ends up, but into the biology that determines how well the vascular system continues to respond along the way.
References
· Fryar, C. D., Kit, B., Carroll, M. D., & Afful, J. (2024). Hypertension prevalence, awareness, treatment, and control among adults age 18 and older: United States, August 2021–August 2023 (NCHS Data Brief No. 511). National Center for Health Statistics. https://doi.org/10.15620/cdc/164016
· Fu, J., Zou, J., Chen, C., Li, H., Wang, L., & Zhou, Y. (2018). Hydrogen molecules (H2) improve perfusion recovery via antioxidant effects in experimental peripheral arterial disease. Molecular medicine reports, 18(6), 5009–5015. https://doi.org/10.3892/mmr.2018.9546
· Godo, S., & Shimokawa, H. (2017). Endothelial Functions. Arteriosclerosis, thrombosis, and vascular biology, 37(9), e108–e114. https://doi.org/10.1161/ATVBAHA.117.309813
· Iketani, M., Sekimoto, K., Igarashi, T., Takahashi, M., Komatsu, M., Sakane, I., Takahashi, H., Kawaguchi, H., Ohtani-Kaneko, R., & Ohsawa, I. (2018). Administration of hydrogen-rich water prevents vascular aging of the aorta in LDL receptor-deficient mice. Scientific reports, 8(1), 16822. https://doi.org/10.1038/s41598-018-35239-0
· Ishibashi, T., Kawamoto, K., Matsuno, K., Ishihara, G., Baba, T., & Komori, N. (2020). Peripheral endothelial function can be improved by daily consumption of water containing over 7 ppm of dissolved hydrogen: A randomized controlled trial. PloS one, 15(5), e0233484. https://doi.org/10.1371/journal.pone.0233484
· Janaszak-Jasiecka, A., Płoska, A., Wierońska, J. M., Dobrucki, L. W., & Kalinowski, L. (2023). Endothelial dysfunction due to eNOS uncoupling: molecular mechanisms as potential therapeutic targets. Cellular & molecular biology letters, 28(1), 21. https://doi.org/10.1186/s11658-023-00423-2
· Ji, H., Sun, H., Zhang, Y., Zhao, Z., Gao, X., Wang, C., Yang, Y., Zhang, X., Gao, J., Man, D., Yang, Q., Yang, Y., Yue, C., Chen, C., Ding, X., & Ni, T. (2024). Effectiveness and safety of hydrogen inhalation therapy as an additional treatment for hypertension in real-world practice: a retrospective, observational study in China. Frontiers in cardiovascular medicine, 11, 1391282. https://doi.org/10.3389/fcvm.2024.1391282
· Liu, B., Jiang, X., Xie, Y., Jia, X., Zhang, J., Xue, Y., & Qin, S. (2022). The effect of a low dose hydrogen-oxygen mixture inhalation in midlife/older adults with hypertension: A randomized, placebo-controlled trial. Frontiers in pharmacology, 13, 1025487. https://doi.org/10.3389/fphar.2022.1025487
· Mu, Q., Lv, K., Yu, J., Chu, S., Zhang, L., Kong, L., Zhang, L., Tian, Y., Jia, X., Liu, B., Wei, Y., & Yang, N. (2022). Hydrogen Repairs LPS-Induced Endothelial Progenitor Cells Injury via PI3K/AKT/eNOS Pathway. Frontiers in pharmacology, 13, 894812. https://doi.org/10.3389/fphar.2022.894812
· Pew Research Center. (2026, June 17). About 4 in 10 U.S. adults have a smartwatch. https://www.pewresearch.org/chart/about-4-in-10-u-s-adults-have-a-smartwatch/
· Poredoš, P., Cífková, R., Marie Maier, J. A., Nemcsik, J., Šabovič, M., Jug, B., Ježovnik, M. K., Schernthaner, G. H., Antignani, P. L., Catalano, M., Fras, Z., Höbaus, C., Nicolaides, A. N., Paraskevas, K. I., Reiner, Ž., Wohlfahrt, P., Poredoš, P., & Blinc, A. (2022). Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?. Atherosclerosis, 348, 25–35. https://doi.org/10.1016/j.atherosclerosis.2022.03.030
· Renna, N. F., de Las Heras, N., & Miatello, R. M. (2013). Pathophysiology of vascular remodeling in hypertension. International journal of hypertension, 2013, 808353. https://doi.org/10.1155/2013/808353
· Sakai, T., Sato, B., Hara, K., Hara, Y., Naritomi, Y., Koyanagi, S., Hara, H., Nagao, T., & Ishibashi, T. (2014). Consumption of water containing over 3.5 mg of dissolved hydrogen could improve vascular endothelial function. Vascular health and risk management, 10, 591–597. https://doi.org/10.2147/VHRM.S68844
· Suzuki, Y., Giles, W. R., Zamponi, G. W., Kondo, R., Imaizumi, Y., & Yamamura, H. (2024). Ca2+ signaling in vascular smooth muscle and endothelial cells in blood vessel remodeling: a review. Inflammation and regeneration, 44(1), 50. https://doi.org/10.1186/s41232-024-00363-0
· Tejero, J., Shiva, S., & Gladwin, M. T. (2019). Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation. Physiological reviews, 99(1), 311–379. https://doi.org/10.1152/physrev.00036.2017
· Touyz, R. M., Rios, F. J., Alves-Lopes, R., Neves, K. B., Camargo, L. L., & Montezano, A. C. (2020). Oxidative Stress: A Unifying Paradigm in Hypertension. The Canadian journal of cardiology, 36(5), 659–670. https://doi.org/10.1016/j.cjca.2020.02.081
· Xie, K., Wang, W., Chen, H., Han, H., Liu, D., Wang, G., & Yu, Y. (2015). Hydrogen-Rich Medium Attenuated Lipopolysaccharide-Induced Monocyte-Endothelial Cell Adhesion and Vascular Endothelial Permeability via Rho-Associated Coiled-Coil Protein Kinase. Shock (Augusta, Ga.), 44(1), 58–64. https://doi.org/10.1097/SHK.0000000000000365
· Xu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., Harding, I. C., Ebong, E. E., Cameron, S. J., Stewart, A. G., & Weng, J. (2021). Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacological reviews, 73(3), 924–967. https://doi.org/10.1124/pharmrev.120.000096
· Zheng, H., & Yu, Y. S. (2012). Chronic hydrogen-rich saline treatment attenuates vascular dysfunction in spontaneous hypertensive rats. Biochemical pharmacology, 83(9), 1269–1277. https://doi.org/10.1016/j.bcp.2012.01.031